
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5657165/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Normative values for intima–media thickness and distensibility of large arteries in healthy adolescents. Journal of Hypertension, 2005, 23, 1707-1715.	0.3	292
2	Altered Morphologic Properties of Large Arteries in Children with Chronic Renal Failure and after Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2005, 16, 1494-1500.	3.0	246
3	Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatric Nephrology, 2002, 17, 141-149.	0.9	209
4	Left ventricular hypertrophy and arterial wall thickening in children with essential hypertension. Pediatric Nephrology, 2006, 21, 811-819.	0.9	168
5	Intima-media thickness and arterial elasticity in hypertensive children: controlled study. Pediatric Nephrology, 2004, 19, 767-774.	0.9	120
6	Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease. Nature Reviews Nephrology, 2019, 15, 577-589.	4.1	103
7	Four-year data after pediatric renal transplantation: A randomized trial of tacrolimus vs. cyclosporin microemulsion. Pediatric Transplantation, 2005, 9, 498-503.	0.5	98
8	Evolution of large-vessel arteriopathy in paediatric patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2008, 23, 2552-2557.	0.4	97
9	Metabolic Abnormalities, Insulin Resistance, and Metabolic Syndrome in Children With Primary Hypertension. American Journal of Hypertension, 2007, 20, 875-882.	1.0	69
10	Hypertension in dialysed children: the prevalence and therapeutic approach in Poland—a nationwide survey. Nephrology Dialysis Transplantation, 2006, 21, 736-742.	0.4	54
11	Perception of health-related quality of life in children with chronic kidney disease by the patients and their caregivers: Multicentre national study results. Quality of Life Research, 2013, 22, 2889-2897.	1.5	50
12	Corticosteroid-free Kidney Transplantation Improves Growth. Transplantation, 2015, 99, 1178-1185.	0.5	47
13	Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors. Pediatric Nephrology, 2006, 21, 1716-1722.	0.9	44
14	Urinary excretion of endothelin-1 (ET-1), transforming growth factor- 1 (TGF- 1) and vascular endothelial growth factor (VEGF165) in paediatric chronic kidney diseases: results of the ESCAPE trial. Nephrology Dialysis Transplantation, 2007, 22, 3487-3494.	0.4	43
15	Bioimpedance and inferior vena cava diameter for assessment of dialysis dry weight. Pediatric Nephrology, 2000, 14, 903-907.	0.9	35
16	Impact of graft loss among kidney diseases with a high risk of post-transplant recurrence in the paediatric population. Nephrology Dialysis Transplantation, 2013, 28, 1031-1038.	0.4	33
17	Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. Pediatric Nephrology, 2005, 20, 622-630.	0.9	30
18	Combined and sequential liver–kidney transplantation in children. Pediatric Nephrology, 2018, 33, 2227-2237.	0.9	29

#	Article	IF	CITATIONS
19	Psychosocial aspects of children and families of children treated with automated peritoneal dialysis. Pediatric Nephrology, 2013, 28, 2157-2167.	0.9	28
20	Outcome of renal transplantation in small infants: a match-controlled analysis. Pediatric Nephrology, 2018, 33, 1057-1068.	0.9	27
21	Anxiety in Children and Adolescents with Chronic Kidney Disease - Multicenter National Study Results. Kidney and Blood Pressure Research, 2013, 37, 579-587.	0.9	24
22	Relationship between serum IgA/C3 ratio and severity of histological lesions using the Oxford classification in children with IgA nephropathy. Pediatric Nephrology, 2015, 30, 1113-1120.	0.9	24
23	Steroid minimization in pediatric renal transplantation: Early withdrawal or avoidance?. Pediatric Transplantation, 2010, 14, 961-967.	0.5	23
24	Steroid withdrawal in renal transplantation. Pediatric Nephrology, 2013, 28, 2107-2112.	0.9	23
25	Longâ€term effect of rituximab in maintaining remission of recurrent and plasmapheresisâ€dependent nephrotic syndrome postâ€renal transplantation – Case report. Pediatric Transplantation, 2011, 15, E121-5.	0.5	22
26	Effects of steroid avoidance and novel protocols on growth in paediatric renal transplant patients. Pediatric Nephrology, 2010, 25, 747-752.	0.9	20
27	Minimizing steroid use in pediatric kidney recipients. Pediatric Transplantation, 2011, 15, 32-36.	0.5	20
28	Delayed graft function and its management in children. Pediatric Nephrology, 2017, 32, 1157-1167.	0.9	18
29	Clinical practice recommendations for recurrence of focal and segmental glomerulosclerosis/steroidâ€resistant nephrotic syndrome. Pediatric Transplantation, 2021, 25, e13955.	0.5	18
30	Eculizumab in Renal Transplantation: A 2017 Update. Annals of Transplantation, 2017, 22, 550-554.	0.5	18
31	Folate, vitamin B 12 , and sulfur amino acid levels in patients with renal failure. Pediatric Nephrology, 2001, 16, 127-132.	0.9	15
32	Soluble CD30 and ELISA-detected human leukocyte antigen antibodies for the prediction of acute rejection in pediatric renal transplant recipients. Transplant International, 2013, 26, 331-338.	0.8	14
33	The status of dental and jaw bones in children and adolescents after kidney and liver transplantation. Annals of Transplantation, 2012, 17, 72-81.	0.5	14
34	Rituximab is not a "magic drug―in post-transplant recurrence of nephrotic syndrome. European Journal of Pediatrics, 2016, 175, 1133-1137.	1.3	13
35	Psychosocial aspects of children and families treated with hemodialysis. Hemodialysis International, 2017, 21, 557-565.	0.4	13
36	Intrafamilial phenotypic variability in a Polish family with Sensenbrenner syndrome and biallelic WDR35 mutations. , 2017, 173, 1364-1368.		13

#	Article	IF	CITATIONS
37	Endothelin-1 inactivating peptidase in the human kidney and urine. Journal of Hypertension, 2000, 18, 475-483.	0.3	12
38	Bone mineral disease in children after renal transplantation in steroidâ€free and steroidâ€treated patients – a prospective study. Pediatric Transplantation, 2011, 15, 205-213.	0.5	11
39	Biologics in renal transplantation. Pediatric Nephrology, 2015, 30, 1087-1098.	0.9	11
40	Fatal rituximabâ€associated lung injury syndrome in a patient treated with rituximab for recurrence of postâ€transplant nephrotic syndrome. Pediatric Transplantation, 2015, 19, E115-20.	0.5	10
41	Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate―or prolongedâ€ŧelease tacrolimus. Clinical Transplantation, 2019, 33, e13698.	0.8	10
42	Favorable fourâ€yr outcome after renal transplantation in a patient with complement factor H antibody and <scp>CFHR</scp> 1/ <scp>CFHR</scp> 3 gene mutationâ€associated <scp>HUS</scp> . Pediatric Transplantation, 2015, 19, E130-4.	0.5	9
43	Interfamilial clinical variability in four <scp>Polish</scp> families with cranioectodermal dysplasia and identical compound heterozygous variants in <scp><i>WDR35</i></scp> . American Journal of Medical Genetics, Part A, 2021, 185, 1195-1203.	0.7	8
44	Arterial hypertension with brachydactyly in a 15-year-old boy. Pediatric Nephrology, 2003, 18, 814-819.	0.9	7
45	Tubulointerstitial nephritis with uveitis: clinico-pathological and immunological study. Pediatric Nephrology, 2002, 17, 683-688.	0.9	6
46	Disease-related social situation in family of children with chronic kidney disease – parents` assessment. A multicentre study. Annals of Agricultural and Environmental Medicine, 2014, 21, 876-881.	0.5	6
47	Eltrombopag (thrombopoietinâ€receptor agonist) and plasmapheresis as rescue therapy of acute postâ€renal transplant immune thrombocytopenia in a child with Schimke immunoâ€osseous dysplasia—case report. Pediatric Transplantation, 2016, 20, 1148-1151.	0.5	5
48	Comparative pharmacokinetics of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate―or prolongedâ€release tacrolimus. Pediatric Transplantation, 2018, 22, e13289.	0.5	5
49	The Role of Complement Component C3 Activation in the Clinical Presentation and Prognosis of IgA Nephropathy—A National Study in Children. Journal of Clinical Medicine, 2021, 10, 4405.	1.0	5
50	Torque teno (TTV) viral load as a biomarker of immunosuppressive strength after kidney transplantation in children. Pediatric Nephrology, 2021, 36, 1-3.	0.9	4
51	Non-Hodgkin lymphoma after liver and kidney transplantation in children. Experience from one center. Advances in Clinical and Experimental Medicine, 2020, 29, 197-202.	0.6	4
52	Non-Hodgkin lymphoma after pediatric kidney transplantation. Pediatric Nephrology, 2022, 37, 1759-1773.	0.9	4
53	Kidney Transplantation in Children with Thrombosed Inferior Caval Vein – Atypical Vascular Anastomoses. Annals of Transplantation, 2019, 24, 25-29.	0.5	3
54	Long-Term Follow-Up of Renal Function in Children after Liver Transplantation—A Single Center Retrospective Study. Children, 2021, 8, 633.	0.6	3

#	Article	IF	CITATIONS
55	The impact of donor-specific antibodies on graft outcome in pediatric renal transplantation from deceased donors. Annals of Transplantation, 2011, 16, 32-39.	0.5	3
56	Occurrence of Portal Hypertension and Its Clinical Course in Patients With Molecularly Confirmed Autosomal Recessive Polycystic Kidney Disease (ARPKD). Frontiers in Pediatrics, 2020, 8, 591379.	0.9	2
57	Blastomyces in pathological lesions on oral mucous membrane in children and adolescents after transplant and with kidney or liver diseases. Journal of Stomatology, 2012, 65, 676-692.	0.1	2
58	Coexistent Takayasu arteritis and erythrokeratodermia variabilis: A case report. Pediatrics International, 2006, 48, 166-168.	0.2	1
59	Sepsa w 2014 roku – kontrowersje i nowości. Pediatria Polska, 2015, 90, 54-65.	0.1	1
60	Growth hormone therapy in pediatric kidney transplantation—the long-term clinical benefits beyond improvement of growth after withdrawal of pre-transplant therapy. Pediatric Nephrology, 2021, , 1.	0.9	1
61	Severe acute cardiotoxicity following two intravenous doses of cyclophosphamide in an adolescent treated for rapidly progressive glomerulonephritis. Kardiologia Polska, 2016, 74, 1027-1027.	0.3	1
62	Second and Third Generational Advances in Therapies of the Immune-Mediated Kidney Diseases in Children and Adolescents. Children, 2022, 9, 536.	0.6	1
63	Genetyczne i autoimmunologiczne mikroangiopatie zakrzepowe u dzieci – wspóÅ,czesna strategia diagnostyki i leczenia. Pediatria Polska, 2016, 91, 295-300.	0.1	0
64	Five-Year Follow-Up and Successful Kidney Transplantation in a Girl with a Severe Phenotype of Pierson Syndrome. Nephron, 2021, 145, 579-584.	0.9	0
65	Evaluation of Cumulative Effect of Standard Triple Immunosuppression on Prevention of De Novo Donor Specific Antibodies (dnDSA) Production in Children after Kidney Transplantation—A	0.6	0